ANTI-AMYLOID THERAPY OF ALZHEIMER’S DISEASE: CURRENT STATE AND PROSPECTS
A leading role in the development of potential drugs for the treatment of Alzheimer’s disease has long been given to drugs that were supposed to support endogenous β-amyloid in the monomeric state and destroy soluble oligomers and insoluble β-amyloid aggregates. However, due to the failure of attempts to create such drugs during the last 20 years, at present this strategy is considered hopeless. In this review, based on the latest achievements in understanding the molecular causes of cerebral amyloidosis in animal models of Alzheimer’s disease, a new approach to anti-amyloid therapy of this pathology is proposed.